Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 133 weeks of public selections as part of this ongoing live forward-testing. ...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Outperform rating and $128 (31% upside) price target at Oppenheimer. More news on: Alnylam Pharmaceuticals, Inc., Amarin Corporation plc, CytomX Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The biotech sector has been one of the high growth spaces over the past decade or so. It remains one of the hottest sectors for stock market investors. When a particular sector has the potential for expansion than even smaller companies, like penny stocks , in the sector have growth opportuniti...
Exicure (NASDAQ: XCUR ) +30% on collaboration with Allergan in hair loss disorders. More news on: Exicure, Inc., Opera Limited, Ping Identity Holding Corp., Stocks on the move, Read more ...
Exicure (NASDAQ: XCUR ) will collaborate with Allergan (NYSE: AGN ) subsidiary Allergan Pharmaceuticals International to discover and develop treatments for hair loss disorders based on Exicure's proprietary SNA technology. More news on: Exicure, Inc., Allergan plc, Healthcare stocks new...
- Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SN...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann, chief executive officer Exicure, Inc. (Nasdaq: XCUR), has been named to Crain’s Chicago Business magaz...
Exicure (NASDAQ: XCUR ): Q3 GAAP EPS of -$0.09 misses by $0.02 . More news on: Exicure, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the third quarter ended September 30, 2019 and provided an update on corporate progress. “Throughou...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its chief financial officer, David Snyder, will give a company update on Tuesday, October 22, 2019 at 11:00am PT at the 2019 B...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-3.60% Change Percent:
Exicure Inc. Company Name:
XCUR Stock Symbol:
OTCMKTS Market:
Exicure Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...